Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 9.49M 11.84M 16.31M |
---|---|---|---|---|---|
Net income 2023 * | -11M -13.72M -18.91M | Net income 2024 * | -17M -21.21M -29.22M | EV / Sales 2023 * | - |
Net Debt 2023 * | 10.76M 13.42M 18.49M | Net Debt 2024 * | 28.9M 36.05M 49.67M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.65
x | P/E ratio 2024 * |
-0.45
x | Employees | 17 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 63.35% |
Current month | +2.22% | ||
1 month | +2.22% | ||
6 months | -11.54% | ||
Current year | +9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 15-12-31 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 23-10-02 |
Simon Wallwork
SEC | Corporate Secretary | - | 21-06-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 22-01-15 |
William Paris
BRD | Director/Board Member | 73 | 21-09-21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21-09-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 11.5 | 0.00% | 0 |
24-04-30 | 11.5 | 0.00% | 0 |
24-04-29 | 11.5 | 0.00% | 0 |
24-04-26 | 11.5 | 0.00% | 0 |
24-04-25 | 11.5 | 0.00% | 0 |
Delayed Quote London S.E., April 30, 2024 at 11:35 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.89M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- BVX Stock